Milestone Pharmaceuticals Inc (MIST) Stock Price, Quote & News

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collabora...

Industry: Biotechnology

Sector: Healthcare

Phone: 514 336 0444

Website: www.milestonepharma.com

Address:

1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada

CashisKing_ Nov. 14 at 9:58 PM

$MIST

0 · Reply

TwongStocks Nov. 14 at 9:14 PM

$MIST Trails Edge filed an updated 13G https://www.sec.gov/Archives/edgar/data/1408443/000149315225023424/xslSCHEDULE_13G_X01/primary_doc.xml Reporting benficial ownership of 9,017,880 shares which consists of: • 3,833,333 shares held directly by Trails Edge Biotechnology • 5,184,547 Series A warrants held directly by Trails Edge Biotechnology Due to the 9.99% blocker provision, the filing excludes the following warrants: • 148,786 Series A warrants • 5,333,333 Series B warrants Compared to their previous filing, Trails Edge sold 1.5m shares. Total number of warrants remains the same. Numbers from their previous 13G filing 👇

2 · Reply

Bionco Nov. 14 at 9:11 PM

$MIST not bad today!

0 · Reply

Tonyboner Nov. 14 at 6:43 PM

$MIST Warrant seller is back fading the price

1 · Reply

Stockseeking Nov. 14 at 6:40 PM

$MIST For comparison, FBIO PDUFA Sep 30, a day before PDUFA, 3.72; Sept 4, sp 2.8; Sept 5 sp 3.71. Expect a similar move for MIST next week and days before PDUFA, to > 3.05

0 · Reply

squiggleburp Nov. 14 at 6:21 PM

$MIST wowowowowowowowowo. Got in just in the knock of time. Bye-

0 · Reply

Acemaker12 Nov. 14 at 6:08 PM

$MIST Approval then BO. But at what price?

2 · Reply

Diverstj981 Nov. 14 at 5:59 PM

$MIST They're trying everything they can to keep this under $2.

0 · Reply

PsychTrades Nov. 14 at 5:24 PM

$MIST uh oh, here we go 🍻

0 · Reply

OGLUCIDBULL Nov. 14 at 5:18 PM

$MIST wait you’re telling me this dummy is wrong again for the 16th time?

0 · Reply

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Nov 4, 2025, 4:05 PM EST - 10 days ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2025, 8:00 AM EST - 11 days ago

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Oct 9, 2025, 8:00 AM EDT - 5 weeks ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Aug 19, 2025, 8:00 AM EDT - 3 months ago

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 12, 2025, 7:05 AM EDT - 3 months ago

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Jul 18, 2025, 2:16 PM EDT - 4 months ago

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Jul 11, 2025, 2:37 PM EDT - 4 months ago

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Jul 11, 2025, 9:30 AM EDT - 4 months ago

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Jul 11, 2025, 6:01 AM EDT - 4 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:00 AM EDT - 4 months ago

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Jul 7, 2025, 10:01 AM EDT - 4 months ago

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Jun 16, 2025, 8:00 AM EDT - 5 months ago

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

May 28, 2025, 8:00 AM EDT - 6 months ago

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 7:04 AM EDT - 6 months ago

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Apr 4, 2025, 2:30 PM EDT - 8 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI ARGX CCL CEPU CF CROX CUK

Mar 28, 2025, 10:24 AM EDT - 8 months ago

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

Mar 28, 2025, 7:06 AM EDT - 8 months ago

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Mar 28, 2025, 7:00 AM EDT - 8 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 21, 2025, 3:18 PM EDT - 8 months ago

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Mar 20, 2025, 8:00 AM EDT - 8 months ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Mar 13, 2025, 7:08 AM EDT - 8 months ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Feb 27, 2025, 8:00 AM EST - 9 months ago

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 8:00 AM EST - 9 months ago

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Feb 11, 2025, 8:00 AM EST - 9 months ago

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Jan 28, 2025, 8:00 AM EST - 10 months ago

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Nov 12, 2024, 9:03 AM EST - 1 year ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Aug 8, 2024, 4:17 PM EDT - 1 year ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

May 31, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 13, 2024, 7:15 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 8, 2024, 11:36 AM EDT - 1 year ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Mar 21, 2024, 7:14 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Feb 29, 2024, 4:01 PM EST - 1 year ago

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 28, 2024, 4:37 PM EST - 1 year ago

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Jan 2, 2024, 7:06 AM EST - 2 years ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT RPID

Dec 26, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Nov 21, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 6:57 AM EST - 2 years ago

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Nov 11, 2023, 10:00 AM EST - 2 years ago

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Oct 24, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Sep 27, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

CashisKing_ Nov. 14 at 9:58 PM

$MIST

0 · Reply

TwongStocks Nov. 14 at 9:14 PM

2 · Reply

Bionco Nov. 14 at 9:11 PM

$MIST not bad today!

0 · Reply

Tonyboner Nov. 14 at 6:43 PM

$MIST Warrant seller is back fading the price

1 · Reply

Stockseeking Nov. 14 at 6:40 PM

$MIST For comparison, FBIO PDUFA Sep 30, a day before PDUFA, 3.72; Sept 4, sp 2.8; Sept 5 sp 3.71. Expect a similar move for MIST next week and days before PDUFA, to > 3.05

0 · Reply

squiggleburp Nov. 14 at 6:21 PM

$MIST wowowowowowowowowo. Got in just in the knock of time. Bye-

0 · Reply

Acemaker12 Nov. 14 at 6:08 PM

$MIST Approval then BO. But at what price?

2 · Reply

Diverstj981 Nov. 14 at 5:59 PM

$MIST They're trying everything they can to keep this under $2.

0 · Reply

PsychTrades Nov. 14 at 5:24 PM

$MIST uh oh, here we go 🍻

0 · Reply

OGLUCIDBULL Nov. 14 at 5:18 PM

$MIST wait you’re telling me this dummy is wrong again for the 16th time?

0 · Reply

PortfolioMgmt23 Nov. 14 at 5:07 PM

$MIST LOL, 1 Million Shares short returned in the last 5 hours. Ouch.

0 · Reply

Porki Nov. 14 at 4:53 PM

$MIST someone is putting a wall up on 2.05….take it down!

0 · Reply

keokeostwiz Nov. 14 at 4:52 PM

$MIST Volume of shares being thrown out looks like company using ATM.......GL

1 · Reply

10sense Nov. 14 at 4:47 PM

$MIST I would suppose that I'm not the only one making a sizable bet on this one

0 · Reply

FitzCatalyst Nov. 14 at 4:44 PM

$MIST

0 · Reply

Stockseeking Nov. 14 at 4:41 PM

$MIST Prior to PDUFA, 3.05 After approval 3.55 long-term >5x

2 · Reply

Orlandotrader Nov. 14 at 4:34 PM

$MIST Smart Money Arriving.

0 · Reply

Lh2838 Nov. 14 at 4:32 PM

$MIST we back

0 · Reply

JanetBSmellin Nov. 14 at 4:31 PM

$MIST Great to see legitimate buying with only two decimal places. The .xxxx orders are panicking algos. Not going to work forever.

0 · Reply

Stockseeking Nov. 14 at 4:29 PM

$MIST close around 2.10 and going up to PDUFA around 3

1 · Reply

Rroper Nov. 14 at 4:27 PM

$MIST Very nice me likesthis action. See where we land.

0 · Reply

Diverstj981 Nov. 14 at 4:25 PM

$MIST Theres $2. Let's keep climbing into the close.

0 · Reply

Market Cap	164.04M
Revenue (ttm)	0.00
Net Income (ttm)	-41.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,143,200
Avg Vol	1,392,988
Day's Range	N/A - N/A
Shares Out	84.99M
Stochastic %K	74%
Beta	0.54
Analysts	Sell
Price Target	$3.50